Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05887882 · ClinicalTrials.gov registry record · Phase 1

Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors

A Phase 1 study of Pediatric Brain Tumor and Pediatric Neoplasm, sponsored by Sabine Mueller, MD, PhD.

Recruiting
Registry status
Phase 1
Development phase
24
Enrollment target
8
Study locations

NCT05887882: Recruiting Phase 1 study of Pediatric Brain Tumor and Pediatric Neoplasm, sponsored by Sabine Mueller, MD, PhD.

NCT05887882 is a Phase 1 study of Pediatric Brain Tumor and Pediatric Neoplasm that is actively recruiting participants, run by Sabine Mueller, MD, PhD. The registered enrollment target is 24 participants, below the 42-participant average among 9 other Pediatric Brain Tumor trials with a reported enrollment target (43% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05887882, a Phase 1 study of Pediatric Brain Tumor and Pediatric Neoplasm, is actively recruiting participants, sponsored by Sabine Mueller, MD, PhD.

RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
8
Study locations

Study Summary

This phase I trial tests the safety, side effects, and best dose of ex vivo expanded natural killer cells in treating patients with cancerous (malignant) tumors affecting the upper part of the brain (supratentorial) that have come back (recurrent) or that are growing, spreading, or getting worse (progressive). Natural killer (NK) cells are immune cells that recognize and get rid of abnormal cells in the body, including tumor cells and cells infected by viruses. NK cells have been shown to kill different types of cancer, including brain tumors in laboratory settings. Giving NK cells from unrelated donors who are screened for optimal cell qualities and determined to be safe and healthy may be effective in treating supratentorial malignant brain tumors in children and young adults.

Conditions Studied

Pediatric Brain Tumor Pediatric Neoplasm Recurrent Pediatric Brain Tumor

Interventions

  • OTHER Quality-of-Life Assessment
  • PROCEDURE Magnetic Resonance Imaging (MRI)
  • BIOLOGICAL Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells
  • PROCEDURE Implantation

Study Locations (8)

Alabama

  • University of Alabama Birmingham - Birmingham

California

  • University of California, San Francisco - San Francisco

Indiana

  • Indiana University - Indianapolis

Maryland

  • Johns Hopkins - Baltimore

Missouri

  • Washington University in Saint Louis - St Louis

New Jersey

  • Hackensack University Medical Center - Hackensack

Ohio

  • Nationwide Children's Hospital - Columbus

Washington

  • Seattle Children's - Seattle

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2024-05-31
Est. Completion 2027-12-31
Phase Phase 1
Sabine Mueller, MD, PhD

12 total trials

What NCT05887882 shows while recruiting

NCT05887882 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 42-participant average among 9 other Pediatric Brain Tumor trials with a reported enrollment target (43% lower).

The record links to 3 conditions, with Pediatric Brain Tumor appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.

NCT05887882 lists 8 locations in 8 states (Alabama, California, Indiana).

Frequently Asked Questions

What is clinical trial NCT05887882 about?

NCT05887882 is a clinical study titled "Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors". This phase I trial tests the safety, side effects, and best dose of ex vivo expanded natural killer cells in treating patients with cancerous (malignant) tumors affecting the upper part of the brain (supratentorial) that have come back (recurrent) or that are growing, spreading, or getting worse (pr...

What is the current status of trial NCT05887882?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-05-31. Estimated completion is 2027-12-31.

What conditions does trial NCT05887882 study?

This clinical trial studies the following conditions: Pediatric Brain Tumor, Pediatric Neoplasm, Recurrent Pediatric Brain Tumor.

What interventions are being tested in trial NCT05887882?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Magnetic Resonance Imaging (MRI) (PROCEDURE), Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells (BIOLOGICAL), Implantation (PROCEDURE).

Who is sponsoring clinical trial NCT05887882?

This trial is sponsored by Sabine Mueller, MD, PhD, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05887882 being conducted?

This trial has 8 study locations across Alabama, California, Indiana, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pediatric Brain Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05887882's enrollment target sits among peer trials

24 8th of 9 higher than 2 of 9 other Pediatric Brain Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pediatric Brain Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05887882

Source: ClinicalTrials.gov NCT05887882, the US trial registry maintained by the National Library of Medicine. NCT05887882 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.